Imugene LtdASX: IMU

Azer-cel demonstrates two additional Complete Responses

· Issued by Imugene Ltd

Filed with ASX · · 5 pages · English

Summary by 6ix AI

Two additional patients have achieved complete responses, bringing the total to four out of seven in the trial cohort. The trial targets patients with relapsed/refractory diffuse large B-cell lymphoma who have previously failed multiple therapies. The company plans to continue monitoring the durability of responses as the trial progresses.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Imugene Ltd on 6ix

Story so far

Earlier from Imugene

Later from Imugene

All Imugene news releases